

GP 1642



PATENT

Our Docket: P-LJ 5037

~~XXXX~~  
7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Reed et al.

Serial No.: 10/001,254

Filed: November 15, 2001

For: NOVEL DEATH DOMAIN PROTEINS

Examiner: Not Yet Known

Group Art Unit: 1642

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on September 24, 2002.

By: Melanie K. Webster  
Melanie K. Webster, Reg. No. 45,201

September 24, 2002  
Date of Signature

Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97(d), enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449.

I hereby state under 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

No fees are deemed necessary in connection with the filing of this Information Disclosure Statement. However, if a

RECEIVED

OCT 02 2002


TECH CENTER 1600/2900

Inventors: Reed et al.  
Serial No.: 10/001,254  
Filed: November 15, 2001  
Page 2

fee is required, the Commissioner is hereby authorized to charge payment of this fee to Deposit Account No. 03-0370.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

Respectfully submitted,



Melanie K. Webster  
Registration No. 45,201  
Telephone: (858) 535-9001  
Facsimile: (858) 535-8949

CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
7<sup>th</sup> Floor  
San Diego, California 92122  
USPTO CUSTOMER NO. 23601

Form PTO 1449 SEP 30 2002 PATENT & TRADEMARK OFFICE	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 5037	SERIAL NO. 10/001,254
	APPLICANT: Reed et al.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: November 15, 2001	GROUP: 1642

### U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	WO 95/10630	04/20/95	PCT			
	WO 98/39429	09/11/98	PCT			

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	Berger et al., "The apoptosis mediator mDAP-3 is a novel member of a conserved family of mitochondrial proteins," <u>Journal of Cell Science</u> , 113:3603-3612 (2000).
	Feinstein et al., "The death domain: a module shared by proteins with diverse cellular functions," <u>Trends in Biochemical Sciences</u> , 20:342-344 (1995).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

OCT 02 2002

TECH CENTER 1600/2900

Form PTO 1449 US Department of Commerce Patent and Trademark Office SEP 30 2002 U.S. PATENT & TRADEMARK OFFICE	ATTY DOCKET NO: P-LJ 5037	SERIAL NO. 10/001,254
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: November 15, 2001	GROUP: 1642

		Han et al., "MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclX <sub>L</sub> and initiates cell death," <u>Proc. Natl. Acad. Sci. USA</u> , 94:11333-11338 (1997).
		Hofmann, K., "The modular nature of apoptic signaling proteins," <u>Cell. Mol. Life Sci.</u> , 55:1113-1123 (1999).
		Kumar et al., "Identification of a Novel Tumor Necrosis Factor- $\alpha$ -inducible Gene, <i>SCC-S2</i> , Containing the Consensus Sequence of a Death Effector Domain of Fas-associated Death Domain-like Interleukin-1 $\beta$ -converting Enzyme-inhibitory Protein," <u>J. Biol. Chem.</u> , 275:2973-2978 (2000).
		Liang and Fesik, "Three-dimensional Structures of Proteins Involved in Programmed Cell Death," <u>J. Mol. Biol.</u> , 274:291-302 (1997).
		Park et al., "Establishment of a High-Throughput Screening System for Caspase-3 Inhibitors," <u>Arch. Pharm. Res.</u> , 23:246-251 (2000).
		Reed and Tomaselli, "Drug discovery opportunities from apoptosis research," <u>Current Opin. Biotech.</u> , 11:586-592 (2000).

RECEIVED

OCT 02 2002

TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.